Sub-Saharan Africa carries 45% of the world's snakebite deaths, a new model estimates
A geostatistical re-estimate puts the global toll at 2.1 million envenomings and 274,000 deaths a year at minimum, with African incidence nearly three times South Asia's — against a short antivenom supply.
Snakebite envenoming has one of the widest uncertainty ranges of any major cause of death, because the people it kills are largely the people health systems do not count. A new geostatistical modelling study revisits the global burden 17 years after the same group's first estimate, and concludes that the earlier figures were probably too low [s1].
The central finding for Africa is stark. Sub-Saharan Africa accounts for 45% of global envenomings and deaths, at nearly three times the incidence observed in South Asia [s1].
The estimate
The study combined a new literature review — covering snakebite, envenoming and mortality published in any language up to 31 March 2025 — with country- and region-level aggregated data and hospital and community survey data [s1]. Geostatistical models related burden to geographic location, using explanatory variables chosen to reflect underlying social and natural environmental conditions, and produced individual-country estimates while accounting for likely underreporting where appropriate [s1].
The models generate a low and a high estimate rather than a single number. At minimum, the authors estimate at least 2.1 million envenomings and 274,000 deaths globally each year; the high estimates run to as many as 7 million envenomings and 513,000 deaths annually [s1].
That is a range in which the upper bound is more than three times the lower on envenomings and nearly double on deaths. It is not a failure of the analysis so much as an honest representation of the input data. The authors name the limitation directly: empirical data are scarce and heterogeneous in many countries, and burden in settings with limited or no direct observation depends on modelling assumptions [s1]. Sub-Saharan Africa is specifically flagged as a region where better epidemiological data are needed for more accurate estimates [s1].
Why the burden concentrates where it does
Low-income countries show the highest incidence and mortality rates [s1]. The mechanism is not mysterious: snakebite is an occupational and domestic hazard of rural agricultural life, and surviving it depends on reaching a facility that stocks a working antivenom within a useful window.
Both halves of that sentence fail more often in the affected regions. A companion policy analysis in PLOS Global Public Health describes snakebite envenoming in sub-Saharan Africa as causing substantial mortality and long-term disability, disproportionately affecting rural and economically vulnerable populations [s2].
The treatment problem
Antivenom is currently the only approved therapy for snakebite [s2]. That single sentence explains why supply is the whole story.
The policy analysis catalogues what stands between a patient and a dose: chronic shortages, fragmented supply chains, high prices and inconsistent product quality, compounded by persistent gaps in human resource capacity and health system infrastructure [s2]. Product quality sits alongside price and availability in that list [s2], which matters because the three fail independently: a facility can have stock, at a price a patient can pay, of a product that does not work for the snakes in that region.
The analysis narrows the many bottlenecks to three interlinked ones: underinvested research capacity, fragile and insufficient manufacturing capacity, and the absence of sustainable financing [s2].
Those three reinforce one another in a way that ordinary market failure language understates. Thin research capacity means poor data on which snakes cause which bites where; poor data means manufacturers cannot size a market; an unsized market means no stable financing; no stable financing means manufacturers exit, which further thins the evidence base about a product nobody is making.
What the policy analysis proposes
Its recommendations are structural rather than clinical. The authors point to emerging political commitments in countries including Kenya, alongside expanding research and manufacturing capacity in the region, as the basis for building a resilient regional ecosystem [s2]. They draw on market-shaping experience from other global health areas, arguing that pooled procurement and blended finance offer potential pathways to stabilise markets, reduce prices and incentivise sustainable production [s2].
The overall prescription is a coordinated policy approach anchored in regional research networks, regional manufacturing and blended finance [s2].
This is an argument from analogy, and it should be read as one. Pooled procurement worked for vaccines and for HIV medicines in settings where demand could be forecast with reasonable confidence. Snakebite's distinguishing feature is that demand cannot currently be forecast — which is exactly what the new burden estimate, with its threefold uncertainty range [s1], demonstrates.
Why the numbers and the supply chain are the same problem
The two papers read as separate stories but describe one loop. Burden estimates are imprecise because cases are not counted; cases are not counted because many victims never reach a facility; they do not reach a facility partly because the facilities within reach do not stock antivenom; and antivenom is not stocked because manufacturers and ministries cannot see the demand that the uncounted cases represent.
That is why the modelling paper's least dramatic conclusion may be its most operationally important: that further improvement in the quality of epidemiological data is required for more accurate burden estimates, particularly in sub-Saharan Africa [s1].
What to watch
The updated estimate arrives 17 years after its predecessor [s1], into a policy environment where the proposed pathways are grounded in existing World Health Organization guidance and, per the policy analysis, some early national political commitment [s2]. The measurable things to watch are narrower than either paper's framing: whether the countries with the highest modelled incidence begin producing routine case reporting that would let the next estimate be an observation rather than a projection, and whether regional manufacturing capacity in Africa expands beyond announcement.
Sources
- Estimates of global burden of snakebite: A literature review and geostatistical modelling study, PLOS Medicine, 25 August 2026
- From scarcity to sustainability: Policy pathways for equitable snakebite antivenom access in Africa, PLOS Global Public Health, 19 May 2026
Sources
- Estimates of global burden of snakebite: A literature review and geostatistical modelling study — PLOS Medicine , August 25, 2026
- From scarcity to sustainability: Policy pathways for equitable snakebite antivenom access in Africa — PLOS Global Public Health , May 19, 2026
Eight nanobodies from an alpaca and a llama neutralised 17 African snake venoms
The experimental recombinant antivenom outperformed a plasma-derived product in mice and cut tissue necrosis. It has not been tested in a single human, and the paper does not address cost or manufacturing at scale.
Bhutan becomes first South-East Asia country validated free of dog-borne rabies
WHO validated Bhutan's elimination of dog-transmitted human rabies, a disease almost always fatal once symptoms appear. The country has recorded zero such deaths since June 2023.
Timor-Leste clears trachoma, ending the disease as a problem across South-East Asia
WHO validated Timor-Leste's elimination of trachoma, the last suspected focus in its South-East Asia Region. A 2025 survey of 4,949 young children found no transmission requiring intervention.
Nearly 200,000 doses of a twice-yearly HIV shot are out in Africa. Supply is the limit.
Nine countries have launched lenacapavir for HIV prevention, with roughly 66,000 people newly started on it. In at least two countries, demand has already outrun the available doses.